| Product Code: ETC9952260 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Industry Life Cycle |
3.4 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Porter's Five Forces |
3.5 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Drugs Type, 2021 & 2031F |
3.6 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Indication Type, 2021 & 2031F |
3.7 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.8 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in the UK |
4.2.2 Growing awareness about PARP inhibitors as a targeted therapy for cancer |
4.2.3 Rising investments in research and development of PARP inhibitors |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for new PARP inhibitors |
4.3.2 High cost associated with PARP inhibitor therapies |
4.3.3 Potential side effects and safety concerns related to PARP inhibitors |
5 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Trends |
6 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Types |
6.1 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Drugs Type |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Drugs Type, 2021- 2031F |
6.1.3 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Talazoparib, 2021- 2031F |
6.1.4 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Veliparib, 2021- 2031F |
6.1.5 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Olaparib, 2021- 2031F |
6.1.6 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Indication Type |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Ovarian Cancer, 2021- 2031F |
6.2.3 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Fallopian Tube Cancer, 2021- 2031F |
6.2.4 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.2.5 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.4 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.5 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.4 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.5 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
7 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Export to Major Countries |
7.2 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Imports from Major Countries |
8 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Key Performance Indicators |
8.1 Number of clinical trials involving PARP inhibitors in the UK |
8.2 Adoption rate of PARP inhibitors in cancer treatment protocols |
8.3 Patient satisfaction and reported outcomes with PARP inhibitor therapies |
9 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Opportunity Assessment |
9.1 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Drugs Type, 2021 & 2031F |
9.2 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Indication Type, 2021 & 2031F |
9.3 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By End User, 2021 & 2031F |
9.4 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Competitive Landscape |
10.1 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here